News &amp; Updates

For patients who have undergone continuous‐flow left ventricular assist device (CF‐LVAD) implantation, treatment with amiodarone may do more harm than good, with a recent study showing that it contributes to increased risk of mortality.

Amiodarone use may reduce survival in continuous‐flow left ventricular assist device recipients

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD

Adjuvant therapy with 5-fluorouracil (5-FU) and low molecular weight heparin in high-risk patients with rhegmatogenous retinal detachment (RRD) does not help prevent the development of proliferative vitreoretinopathy, as shown in a study.

Prophylactic 5-FU plus heparin not effective against proliferative vitreoretinopathy in RRD

Infection + vaccination = The best protection against COVID-19?

13 Jun 2022 by

Individuals with a prior COVID-19 infection and who are fully vaccinated against COVID-19 appear to have the greatest immunity to the virus, according to the SIREN* study.

Infection + vaccination = The best protection against COVID-19?

13 Jun 2022

Haemodialysis delivers urate-lowering benefit to patients with gout, ESRD

In patients with gout and end-stage renal disease (ESRD), haemodialysis appears to have an additional benefit of lowering uric acid (UA) levels, a study has found.

Haemodialysis delivers urate-lowering benefit to patients with gout, ESRD

Pranlukast cuts need for respiratory support in infants with RSV

The use of pranlukast in infants with respiratory syncytial virus (RSV) infections appears to help avoid the need for respiratory support, a recent Japan study has found.

Pranlukast cuts need for respiratory support in infants with RSV

Azithromycin improves asthma control, cuts exacerbations in children

11 Jun 2022

In the treatment of children with poorly controlled asthma, the use of azithromycin helps improve asthma control and reduce exacerbations, according to a study.

Azithromycin improves asthma control, cuts exacerbations in children

11 Jun 2022

Paclitaxel-coated devices in femoropopliteal artery revascularization: Mortality risk fears unfounded?

10 Jun 2022 by

Among patients undergoing femoropopliteal artery revascularization, mortality risk was not affected regardless of whether they were treated with drug-coated devices (DCDs) or non–drug-coated devices (NDCDs), according to updated results of the SAFE-PAD* study presented at SCAI 2022.

Paclitaxel-coated devices in femoropopliteal artery revascularization: Mortality risk fears unfounded?

$Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML$

Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML

Patients with relapsed or refractory FLT3-mutated acute myeloid leukaemia (AML) and with prior exposure to tyrosine kinase inhibitors (TKIs) may benefit from gilteritinib treatment, which leads to better remission and survival outcomes than salvage chemotherapy, a recent study has found.

Gilteritinib a potential treatment option for FLT3-mutated relapsed, refractory AML

OKINADA: TNF inhibition disappoints in knee osteoarthritis

10 Jun 2022 by

Short-term tumour necrosis factor (TNF) inhibition with adalimumab falls short of producing improvements in patients with radiographic knee osteoarthritis, according to the proof-of-concept OKINADA trial presented at this year’s European Alliance of Associations for Rheumatology (EULAR) Congress.

OKINADA: TNF inhibition disappoints in knee osteoarthritis

10 Jun 2022

Obefazimod 50 mg for rheumatoid arthritis delivers in phase II trial